VA
AXSM icon

Verdad Advisers’s Axsome Therapeutics AXSM Stock Holding History

Verdad Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Buy
+5,971
New +$1.03M 1.14% 21

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verdad Advisers's AXSM Position: Q1 2026 in Review

Verdad Advisers opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 5,971 shares worth $1.01M. The stake represents 1.14% of the portfolio and ranks #21 among its holdings.

409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Verdad Advisers held 5,971 shares of Axsome Therapeutics worth $1.01M as of Q1 2026.
  • Axsome Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Axsome Therapeutics made up 1.14% of Verdad Advisers's portfolio in Q1 2026, its #21 holding.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.